Otsuka spells out Phase 3 win in rare kidney disease, Vera’s stock takes a hit
Otsuka has shared the specifics of a late-stage win for a rare kidney disease treatment that’s on track to become its first wholly-owned product to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
